Positive News SentimentPositive NewsNASDAQ:SEEL Seelos Therapeutics (SEEL) Stock Forecast, Price & News $0.90 -0.08 (-8.16%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$0.89▼$0.9950-Day Range$0.66▼$1.0652-Week Range$0.58▼$1.52Volume561,086 shsAverage Volume500,972 shsMarket Capitalization$109.63 millionP/E RatioN/ADividend YieldN/APrice Target$3.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Seelos Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside270.4% Upside$3.33 Price TargetShort InterestHealthy4.77% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.35 out of 5 starsMedical Sector928th out of 981 stocksPharmaceutical Preparations Industry445th out of 466 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $3.33, Seelos Therapeutics has a forecasted upside of 270.4% from its current price of $0.90.Amount of Analyst CoverageSeelos Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.77% of the outstanding shares of Seelos Therapeutics have been sold short.Short Interest Ratio / Days to CoverSeelos Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Seelos Therapeutics has recently decreased by 11.03%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSeelos Therapeutics does not currently pay a dividend.Dividend GrowthSeelos Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SEEL. Previous Next 3.2 News and Social Media Coverage News SentimentSeelos Therapeutics has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.Search Interest6 people have searched for SEEL on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Seelos Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Seelos Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Seelos Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 25.39% of the stock of Seelos Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here About Seelos Therapeutics (NASDAQ:SEEL) StockSeelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.Read More Receive SEEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SEEL Stock News HeadlinesMay 22, 2023 | finance.yahoo.comSeelos Therapeutics to Participate in Two Upcoming Healthcare ConferencesMay 21, 2023 | americanbankingnews.comFY2023 EPS Estimates for Seelos Therapeutics, Inc. (NASDAQ:SEEL) Decreased by Cantor FitzgeraldJune 7, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 17, 2023 | americanbankingnews.comSeelos Therapeutics (NASDAQ:SEEL) Price Target Cut to $4.00May 16, 2023 | msn.comBTIG Maintains Seelos Therapeutics (SEEL) Buy RecommendationMay 16, 2023 | msn.comSeelos Therapeutics Positive Q1 Financials Make For 'The Most Important Year' In Company's HistoryMay 16, 2023 | msn.comCantor Fitzgerald Maintains Seelos Therapeutics (SEEL) Overweight RecommendationMay 16, 2023 | americanbankingnews.comSeelos Therapeutics (NASDAQ:SEEL) Price Target Cut to $2.00 by Analysts at Cantor FitzgeraldJune 7, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 15, 2023 | finanznachrichten.deSeelos Therapeutics, Inc.: Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial ResultsMay 15, 2023 | markets.businessinsider.comSeelos Therapeutics, Inc Q1 Loss decreases, but misses estimatesMay 15, 2023 | msn.comSeelos Therapeutics GAAP EPS of -$0.12 misses by $0.02, revenue of $0.81MMay 15, 2023 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Seelos Therapeutics (SEEL)May 15, 2023 | finance.yahoo.comSeelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial ResultsMay 13, 2023 | marketwatch.com2030, Psychedelic Drugs Market: Trend & OutlookMay 5, 2023 | finance.yahoo.comSeelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual MeetingApril 14, 2023 | msn.comATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of TodayApril 6, 2023 | msn.comUnusual Call Option Trade in Seelos Therapeutics (SEEL) Worth $17.57KApril 4, 2023 | finance.yahoo.comSeelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access ProgramMarch 31, 2023 | markets.businessinsider.comBTIG Remains a Buy on Seelos Therapeutics (SEEL)March 30, 2023 | marketwatch.comPsychedelic Medicine Market research Report with Analysis 2023 To 2030March 30, 2023 | marketwatch.comPsychedelic Drugs Market Analysis, Industry Report, Trends 2029March 29, 2023 | finance.yahoo.comSeelos Therapeutics Announces Business Update on its Key ProgramsMarch 25, 2023 | americanbankingnews.comSeelos Therapeutics (NASDAQ:SEEL) Price Target Lowered to $4.00 at BenchmarkMarch 14, 2023 | msn.comSeelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of TodayMarch 10, 2023 | marketwatch.comSeelos Therapeutics Prices Direct Offering With Proceeds of $11.2MMarch 10, 2023 | finance.yahoo.comSeelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common StockSee More Headlines SEEL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SEEL Company Calendar Last Earnings5/15/2023Today6/07/2023Next Earnings (Estimated)8/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SEEL CUSIPN/A CIK1017491 Webwww.seelostherapeutics.com Phone(646) 293-2100Fax858-436-8155Employees15Year Founded2016Price Target and Rating Average Stock Price Forecast$3.33 High Stock Price Forecast$4.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+270.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,530,000.00 Net MarginsN/A Pretax Margin-9,030.20% Return on Equity-10,287.49% Return on Assets-209.12% Debt Debt-to-Equity Ratio1.36 Current Ratio0.60 Quick Ratio0.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.10) per share Price / Book-9.00Miscellaneous Outstanding Shares121,810,000Free Float114,015,000Market Cap$109.63 million OptionableNot Optionable Beta1.73 Social Links Key ExecutivesRaj MehraChairman, President & Chief Executive OfficerMichael GolembiewskiChief Financial OfficerTimothy J. WhitakerChief Medical OfficerGopal KrishnaHead-Manufacturing & Technical OperationsKaren FusaroSenior Vice President & Head-Clinical OperationsKey CompetitorsGossamer BioNASDAQ:GOSSShattuck LabsNASDAQ:STTKAtossa TherapeuticsNASDAQ:ATOSCapricor TherapeuticsNASDAQ:CAPRCelularityNASDAQ:CELUView All CompetitorsInstitutional OwnershipGeode Capital Management LLCBought 22,118 shares on 5/16/2023Ownership: 0.934%Susquehanna International Group LLPSold 134,200 shares on 5/16/2023Ownership: 0.000%Gendell Jeffrey LBought 159,295 shares on 5/15/2023Ownership: 4.161%Uniplan Investment Counsel Inc.Sold 50,695 shares on 5/15/2023Ownership: 0.925%BlackRock Inc.Sold 124,552 shares on 5/12/2023Ownership: 1.364%View All Institutional Transactions SEEL Stock - Frequently Asked Questions Should I buy or sell Seelos Therapeutics stock right now? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last twelve months. There are currently for the stock. The consensus among Wall Street analysts is that investors should "n/a" SEEL shares. View SEEL analyst ratings or view top-rated stocks. What is Seelos Therapeutics' stock price forecast for 2023? 0 brokers have issued 1 year target prices for Seelos Therapeutics' shares. Their SEEL share price forecasts range from $2.00 to $4.00. On average, they predict the company's stock price to reach $3.33 in the next year. This suggests a possible upside of 270.4% from the stock's current price. View analysts price targets for SEEL or view top-rated stocks among Wall Street analysts. How have SEEL shares performed in 2023? Seelos Therapeutics' stock was trading at $0.6790 at the start of the year. Since then, SEEL stock has increased by 32.5% and is now trading at $0.90. View the best growth stocks for 2023 here. When is Seelos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023. View our SEEL earnings forecast. How were Seelos Therapeutics' earnings last quarter? Seelos Therapeutics, Inc. (NASDAQ:SEEL) posted its quarterly earnings results on Monday, May, 15th. The company reported ($0.12) earnings per share for the quarter. The company had revenue of $0.81 million for the quarter. What ETF holds Seelos Therapeutics' stock ? AdvisorShares Psychedelics ETF holds 399,133 shares of SEEL stock, representing 5.54% of its portfolio. What other stocks do shareholders of Seelos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), iBio (IBIO) and OPKO Health (OPK). What is Seelos Therapeutics' stock symbol? Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL." Who are Seelos Therapeutics' major shareholders? Seelos Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Gendell Jeffrey L (4.16%), BlackRock Inc. (1.36%), Mirae Asset Global Investments Co. Ltd. (1.18%), Geode Capital Management LLC (0.93%), Uniplan Investment Counsel Inc. (0.93%) and Wealth Effects LLC (0.78%). Insiders that own company stock include Daniel J O'connor and Raj Mehra. View institutional ownership trends. How do I buy shares of Seelos Therapeutics? Shares of SEEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Seelos Therapeutics' stock price today? One share of SEEL stock can currently be purchased for approximately $0.90. How much money does Seelos Therapeutics make? Seelos Therapeutics (NASDAQ:SEEL) has a market capitalization of $109.63 million. How can I contact Seelos Therapeutics? Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The official website for the company is www.seelostherapeutics.com. The company can be reached via phone at (646) 293-2100, via email at anthony.marciano@seelostx.com, or via fax at 858-436-8155. This page (NASDAQ:SEEL) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seelos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.